Workflow
Early Detection
icon
Search documents
Exact Sciences CEO on Launch of Multi-Cancer Blood Test
Bloomberg Television· 2025-09-15 19:30
For the layman ear, which most of us obviously are. How this test works and why you exclude breast cancer and prostate cancer. Sure.And let's talk about the problem. The problem is that cancer is the number one cause of death among people who are under 85. That's 600,000 people a year and 2 million people are diagnosed.So it's is the number one health problem if you look at it through that lens. And today, we're screening for only four types of cancer. And there are 50 types of cancers and subtypes that we ...
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
Prnewswire· 2025-03-04 13:25
Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [5] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [5]. Recent Offering - Lucid Diagnostics announced subscription agreements to sell 13,939,331 shares of common stock at a price of $1.10 per share, expecting gross proceeds of approximately $15.3 million [1]. - The offering is being managed by Canaccord Genuity as the sole placement agent, with the closing expected around March 5, 2025, subject to customary conditions [2]. Use of Proceeds - The net proceeds from the offering will be used for working capital and other general corporate purposes [2]. Regulatory Information - The securities are being offered under a registration statement on Form S-3, which was declared effective by the SEC on December 6, 2022 [3]. - A prospectus supplement will be filed with the SEC regarding the securities being offered [3]. Product Information - Lucid's EsoGuard® Esophageal DNA Test is designed for early detection of esophageal precancer in at-risk patients, utilizing a noninvasive office procedure with the EsoCheck® Esophageal Cell Collection Device [5].